Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized medicines for neuropsychiatric conditions such as major depressive disorder, bipolar depression, and schizophrenia. It uses brain-biology measures and biomarkers to match drug candidates to patients most likely to respond, aiming to replace trial-and-error prescribing. Pipeline programs include small-molecule candidates designed around core neural processes rather than one-size-fits-all psychiatric drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -17.7 | — |
| Q3 2025 | 0 | — | -14.2 | — |
| Q4 2025 | 0 | — | -16.2 | — |
| Q1 2026 | 0 | — | -26.2 | — |
| Q2 2026 | 0 | — | -27.6 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Metallus Inc. (MTUS), Kronos Worldwide, Inc. (KRO), Phoenix Education Partners, Inc. (PXED), N-able, Inc. (NABL), Yalla Group Limited (YALA), Six Flags Entertainment Corporation (FUN)